Vor Biopharma Inc.
VOR · XNASCIK 1817229fmd_1R3R2SD862RM0W5ZHQJJ2W10KEManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 32 | 48 | 65 | 94 | 93 | 322 |
| Total operating expenses | 43 | 69 | 93 | 126 | 121 | 372 |
| Operating income | (43) | (69) | (93) | (126) | (121) | (372) |
| Interest and investment income | 0 | 0 | 1 | 8 | 4 | 6 |
| Other non-operating income (expense) | 0 | 0 | 1 | 8 | 4 | (324) |
| Net income | (43) | (69) | (92) | (118) | (117) | (696) |
| Net income to common shareholders | (49) | (70) | (92) | (118) | – | – |